NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
Recruiting · NCT07563829 · Registry updated 2026-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 1 | 2026-09-08 | NCT07563829 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| NextPoint Therapeutics, Inc. | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins | Baltimore | United States | 39 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Montefiore | The Bronx | United States | 4 |
| NEXT | Fairfax | United States | 2 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| University of California - San Diego | La Jolla | United States | 4 |